Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHI-101 in Relapsed or Refractory AML
NCT04842370Phase 1Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Jun 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lasmotinib in acute myeloid leukemia (AML), sponsored by Seoul National University Hospital. Primary endpoint: Adverse Events. Status: unknown.
02
Drugs
lasmotinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04842370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842370.